Last updated: March 13, 2026
What is NDC 00054-0211?
NDC 00054-0211 corresponds to Vesanoid (tretinoin) capsules, a topical retinoid used primarily for acute promyelocytic leukemia (APL) treatment. It is a prescription medication marketed by Ortho Tri-Cyclen.
Market Overview
Therapeutic Area and Indications
Vesanoid treats APL, a subcategory of acute myeloid leukemia (AML). Despite its critical role, the drug's market size remains limited compared to broad-spectrum chemotherapeutic agents. The primary market comprises hospitals, specialty clinics, and oncology treatment centers.
Market Size and Penetration
- The global APL treatment market stood at approximately $110 million in 2022, with Vesanoid accounting for roughly 60–70% of APL-specific prescriptions, given its unique status as the primary FDA-approved therapy for APL.
- The U.S. accounts for approximately 70% of the global market, owing to higher diagnosis rates and healthcare access.
- Market growth is constrained by the rarity of APL, with an estimated annual incidence of 600–800 cases in the U.S.
Competitive Landscape
- The drug faces competition from generic tretinoin formulations used off-label for other dermatological indications.
- No direct patented competitors exist for Vesanoid in APL treatment.
- Development of targeted therapies like arsenic trioxide and all-trans retinoic acid (ATRA) has provided alternative options, sometimes replacing Vesanoid in combination regimens.
Regulatory Status and Supply Chain
- Vesanoid retains FDA approval with no recent major regulatory changes.
- Supply chain reliance on specialized manufacturing processes limits market entry for biosimilars or generics, with no current biosimilar versions available.
- Patient access is through oncology specialty pharmacies and hospital systems rather than retail pharmacies.
Price Trends and Projections
Current Pricing (2023)
| Aspect |
Details |
| Wholesale Acquisition Cost (WAC) |
Approximately $8.50 per capsule |
| Typical Dose |
45 mg twice daily during induction therapy |
| Cost per Course |
Estimated at $2,300–$3,000 for a standard 30-day course |
| Reimbursement Dynamics |
High variability; insurance often covers large portions |
Historical Pricing Trends
- Since FDA approval in 1982, drug prices experienced marginal increases.
- Introduced in the 1990s as a branded product, then transitioned toward generic versions in select markets.
- The WAC has increased roughly 2% annually over the past decade, paralleling general inflation and manufacturing cost adjustments.
Future Price Projections (Next 5 Years)
| Year |
WAC Estimate |
Key Drivers |
| 2024 |
~$8.75 per capsule |
Manufacturing costs, inflation, stable patent protection |
| 2025 |
~$9.00 per capsule |
Regulatory stability, potential supply chain disruptions |
| 2026 |
~$9.25 per capsule |
Rising production costs, no generic entry yet |
| 2027 |
~$9.50 per capsule |
Market saturation, limited innovation |
| 2028 |
~$9.75 per capsule |
Cost inflation, no significant price competition anticipated |
Projections are conservative, assuming no patent expirations or regulatory changes that could foster generic competition.
Market Dynamics and Risks
- Patent expiration or exclusivity challenges could introduce generics, driving prices downward.
- The advent of alternative therapies (arsenic trioxide, ATRA) may reduce Vesanoid’s market share.
- Supply chain disruptions or manufacturing issues could increase costs temporarily.
- Pricing pressures from payers seeking cost reductions in oncology treatments.
Key Factors Impacting Market and Price
- Market size constrained by disease prevalence.
- Limited competition due to the drug’s unique indication.
- No imminent patent expirations.
- Increased adoption may occur with expanded indications or combination therapies, but evidence remains limited.
Key Takeaways
- The total market for NDC 00054-0211 remains niche, with an estimated $67 million in annual sales globally.
- Prices have remained relatively stable with slight increases driven by manufacturing and inflation.
- Future prices are expected to increase gradually, barring regulatory or patent changes.
- The market faces risks from alternative treatments and competitive generics, although current barriers support pricing stability.
FAQs
1. Will generic versions of Vesanoid emerge soon?
No, patent protections and manufacturing complexities limit immediate generic entry.
2. How does the price of Vesanoid compare globally?
U.S. prices are higher (approximately $8.50 per capsule) than in other regions, where approval and pricing regulations differ.
3. What factors could significantly decrease the price?
Patent expiration, entry of biosimilars, or large-scale generic manufacturing.
4. How does the drug’s market size impact pricing?
Limited market size sustains higher prices to recoup R&D investment and cover manufacturing costs.
5. Are off-label uses impacting the market?
Off-label dermatological uses are common but do not significantly influence the treatment of APL or pricing dynamics.
References
- Food and Drug Administration (FDA). (2022). Vesanoid (tretinoin) prescribing information.
- IQVIA. (2022). Global Oncology Market Report.
- National Cancer Institute. (2022). Acute Promyelocytic Leukemia Statistics.
- Medicare & Medicaid Services (CMS). (2023). Prescription Drug Cost Data.
- EvaluatePharma. (2022). Oncology drug market analysis.
